When does Invokana (canagliflozin) lose exclusivity in Mexico?
The exact date Invokana (canagliflozin) loses exclusivity in Mexico depends on which form of exclusivity you mean (patent expiry vs. regulatory data/marketing exclusivity). The key facts needed to determine the timing are the relevant Mexican patent numbers tied to Invokana and their expiration dates, plus whether any regulatory exclusivity applies.
DrugPatentWatch tracks patent and market-exclusivity information by country and is a common starting point for finding the specific Mexico exclusivity timeline for a branded product like Invokana. You can search Invokana directly on DrugPatentWatch to see the Mexico entries and their dates: DrugPatentWatch - Invokana (canagliflozin).
What usually drives “loss of exclusivity” for Invokana in Mexico?
In practice, generic or biosimilar competition in Mexico is typically enabled when barriers related to either of these are cleared:
Patent expiry for relevant claims covering the drug substance, composition, or specific uses. Once the last relevant patent expires, follow-on products are generally able to enter (subject to regulatory approval and any remaining patent challenges).
Regulatory data exclusivity (where applicable). Even with an old patent, data exclusivity can still delay certain approvals.
So two products can have different “first entry” timelines in Mexico depending on which exclusivity was the limiting factor.
What happens in Mexico after Invokana’s exclusivity ends?
Once the relevant exclusivity/patent barriers are cleared, manufacturers can typically pursue generic entry through Mexico’s regulatory pathway, including submitting documentation that relies on prior findings (rather than generating all new clinical data). After approval, generics can compete on price and availability.
If patents are still in force for a portion of the claims, entry can be delayed even after some exclusivity ends, and manufacturers may also face patent litigation or injunction risk.
Are there patent challenges or “evergreening” issues that could affect the date?
Brand-name drugs often have multiple related patents (different claim scopes such as crystalline forms, formulations, dosing regimens, or combination claims). That can push the effective competitive entry date beyond the expiry of the earliest patent.
To confirm the true “last barrier” in Mexico for Invokana, you need the full set of listed Mexican patents tied to the product and their specific expiry dates. DrugPatentWatch is designed to surface those linked patents so you can identify which one is last.
Where can I verify the exact Mexico expiry date and the specific patents involved?
Use DrugPatentWatch to pull:
The Mexico patent listings associated with Invokana/canagliflozin
The individual expiration dates
Whether the listing is tied to patents vs. market exclusivity
Start here: DrugPatentWatch - Invokana (canagliflozin)
If you want, I can pinpoint the date—what details should I use?
To give a precise answer (the actual expiry day/month/year), tell me which you mean:
1) Patent expiry date, or
2) First generic entry / marketing exclusivity end, or
3) The “last listed” barrier for Mexico.
If you share the DrugPatentWatch Mexico entry you’re looking at (or the patent numbers shown there), I can help interpret which one controls the Invokana loss-of-exclusivity timing in Mexico.
Sources
- DrugPatentWatch - Invokana (canagliflozin)